Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures.
Consumer satisfaction and social validity were measured during a double-blind, placebo-controlled evaluation of the atypical neuroleptic risperidone in treating severe aberrant behavior of persons with developmental disabilities. First, a satisfaction survey was completed after a medication trial by each participant's caregiver. Results showed that 100% of the caregivers felt that participation was a positive experience for themselves and participants. Second, 52 community members viewed videotapes of 5 participants during a clinical interview when they were taking either placebo or risperidone. Raters also indicated that when on the medication, participants displayed fewer aberrant behaviors, were less irritable, in a better mood, and were more responsive to their environment.
McAdam
David B
DB
University of Kansas, Lawrence 66045, USA.
Zarcone
Jennifer R
JR
Hellings
Jessica
J
Napolitano
Deborah A
DA
Schroeder
Stephen R
SR
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001519:Behavior / Q000187:drug effects*; D017028:Caregivers / Q000523:psychology*; D002648:Child; D003258:Consumer Behavior; D018592:Cross-Over Studies; D002658:Developmental Disabilities / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014743:Videotape Recording
D014150:Antipsychotic Agents; D018967:Risperidone